Population Pharmacokinetics and Dose Evaluation of Cycloserine among Patients with Multidrug-Resistant Tuberculosis under Standardized Treatment Regimens.
cycloserine
dosing evaluation
drug concentration thresholds
minimum inhibitory concentration
multidrug-resistant tuberculosis
population pharmacokinetics
Journal
Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061
Informations de publication
Date de publication:
17 05 2023
17 05 2023
Historique:
medline:
19
5
2023
pubmed:
25
4
2023
entrez:
25
4
2023
Statut:
ppublish
Résumé
Although cycloserine is a recommended drug for the treatment of multidrug-resistant tuberculosis (MDR-TB) according to World Health Organization (WHO), few studies have reported on pharmacokinetics (PK) and/or pharmacodynamics (PD) data of cycloserine in patients with standardized MDR-TB treatment. This study aimed to estimate the population PK parameters for cycloserine and to identify clinically relevant PK/PD thresholds, as well as to evaluate the current recommended dosage. Data from a large cohort with full PK curves was used to develop a population PK model. This model was used to estimate drug exposure in patients with MDR-TB from a multicentre prospective study in China. The classification and regression tree was used to identify the clinically relevant PK/PD thresholds. Probability of target attainment was analyzed to evaluate the currently recommended dosing strategy. Cycloserine was best described by a two-compartment disposition model. A percentage of time concentration above MICs (T
Identifiants
pubmed: 37097151
doi: 10.1128/aac.01700-22
pmc: PMC10190270
doi:
Substances chimiques
Cycloserine
95IK5KI84Z
Antitubercular Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0170022Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Infect Dis Poverty. 2020 Jul 18;9(1):97
pubmed: 32682446
Eur Respir J. 2022 Mar 24;59(3):
pubmed: 34737224
J Infect Dis. 2015 Jun 15;211 Suppl 3:S96-S106
pubmed: 26009618
Int J Antimicrob Agents. 2017 Jun;49(6):677-687
pubmed: 28408267
J Bras Pneumol. 2010 Sep-Oct;36(5):641-56
pubmed: 21085831
Drugs R D. 2019 Sep;19(3):289-296
pubmed: 31396892
Clin Infect Dis. 2018 Nov 28;67(suppl_3):S308-S316
pubmed: 30496460
Antimicrob Agents Chemother. 2018 Feb 23;62(3):
pubmed: 29311073
Nat Commun. 2019 Sep 13;10(1):4177
pubmed: 31519879
Haemophilia. 2015 Nov;21(6):715-22
pubmed: 26248714
Antimicrob Agents Chemother. 2020 Oct 20;64(11):
pubmed: 32816738
Int J Tuberc Lung Dis. 2022 Jun 1;26(6):483-499
pubmed: 35650702
Eur Respir J. 2022 Mar 24;59(3):
pubmed: 34949698
Euro Surveill. 2013 Apr 18;18(16):20455
pubmed: 23611033
Int J Infect Dis. 2021 Apr;105:688-694
pubmed: 33684562
Clin Pharmacokinet. 2020 Jul;59(7):899-910
pubmed: 31981103
Br J Clin Pharmacol. 2019 Sep;85(9):1946-1956
pubmed: 31046167
ACS Chem Biol. 2017 May 19;12(5):1235-1244
pubmed: 28272868
Int J Tuberc Lung Dis. 2011 Apr;15(4):502-9
pubmed: 21396210
Clin Infect Dis. 2021 Nov 2;73(9):e3520-e3528
pubmed: 33070176
Clin Microbiol Infect. 2021 Feb;27(2):288.e1-288.e4
pubmed: 33198949
J Infect Dis. 2013 Nov 1;208(9):1464-73
pubmed: 23901086
Antimicrob Agents Chemother. 2019 Apr 25;63(5):
pubmed: 30858211
Eur Respir J. 2019 Dec 19;54(6):
pubmed: 31601711
Clin Infect Dis. 2012 Jul;55(2):169-77
pubmed: 22467670